Prime Medicine Inc (PRME)
3.345
-0.25
(-6.95%)
USD |
NASDAQ |
Nov 15, 16:00
3.34
0.00 (0.00%)
After-Hours: 20:00
Prime Medicine Enterprise Value: 263.21M for Nov. 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 15, 2024 | 263.21M |
| November 14, 2024 | 296.00M |
| November 13, 2024 | 343.87M |
| November 12, 2024 | 391.09M |
| November 11, 2024 | 400.27M |
| November 08, 2024 | 362.23M |
| November 07, 2024 | 362.23M |
| November 06, 2024 | 362.23M |
| November 05, 2024 | 372.73M |
| November 04, 2024 | 343.87M |
| November 01, 2024 | 353.05M |
| October 31, 2024 | 333.38M |
| October 30, 2024 | 358.30M |
| October 29, 2024 | 359.61M |
| October 28, 2024 | 376.66M |
| October 25, 2024 | 353.05M |
| October 24, 2024 | 375.35M |
| October 23, 2024 | 347.80M |
| October 22, 2024 | 409.45M |
| October 21, 2024 | 397.65M |
| October 18, 2024 | 398.96M |
| October 17, 2024 | 322.88M |
| October 16, 2024 | 343.87M |
| October 15, 2024 | 318.95M |
| October 14, 2024 | 313.70M |
| Date | Value |
|---|---|
| October 11, 2024 | 301.90M |
| October 10, 2024 | 294.03M |
| October 09, 2024 | 291.41M |
| October 08, 2024 | 320.26M |
| October 07, 2024 | 303.21M |
| October 04, 2024 | 284.85M |
| October 03, 2024 | 271.73M |
| October 02, 2024 | 274.35M |
| October 01, 2024 | 276.98M |
| September 30, 2024 | 332.07M |
| September 27, 2024 | 252.44M |
| September 26, 2024 | 264.44M |
| September 25, 2024 | 246.44M |
| September 24, 2024 | 257.24M |
| September 23, 2024 | 269.24M |
| September 20, 2024 | 296.85M |
| September 19, 2024 | 306.45M |
| September 18, 2024 | 314.85M |
| September 17, 2024 | 317.26M |
| September 16, 2024 | 286.05M |
| September 13, 2024 | 328.06M |
| September 12, 2024 | 323.26M |
| September 11, 2024 | 328.06M |
| September 10, 2024 | 317.26M |
| September 09, 2024 | 278.85M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
246.44M
Minimum
Sep 25 2024
2.302B
Maximum
Nov 11 2022
885.63M
Average
737.52M
Median
Jun 13 2024
Enterprise Value Benchmarks
| Bristol-Myers Squibb Co | 155.74B |
| Molecular Templates Inc | -6.581M |
| CEL-SCI Corp | 34.06M |
| AIM ImmunoTech Inc | 6.697M |
| IGC Pharma Inc | 23.95M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -52.52M |
| Revenue (Quarterly) | 0.209M |
| Total Expenses (Quarterly) | 54.44M |
| EPS Diluted (Quarterly) | -0.44 |
| Profit Margin (Quarterly) | -25.13K% |
| Earnings Yield | -61.58% |